2Seventy Bio Inc (TSVT)

$5.00 +0.01 (0.20%)
Market Cap 266.15M
Revenue (ttm) 37.86M
Net Income (ttm) -57.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -151.22%
Debt to Equity Ratio 0.00
Volume 1,158,100
Avg Vol 1,649,014
Day's Range N/A - N/A
Shares Out 53.23M
Stochastic %K 67%
Beta 1.04
Analysts Hold
Price Target $5.50

Company Profile

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 617 675 7270
Address:
60 Binney Street, Cambridge, United States
fantastex
fantastex Jun. 4 at 8:04 PM
$LYEL this Will get either bought out or merged with $TSVT for a premium. If released data is positive, get ready, it can pump up more to 20 bucks and bought out for 30.
0 · Reply
fantastex
fantastex Jun. 1 at 6:09 PM
$LYEL manufacturing site is in Bothel, WA - same city where the recent $TSVT acquirer ( $BMY) has its own.... Lol it would be easy for the CEOs to have meetings... Coincidence? @valueforme
2 · Reply
valueforme
valueforme May. 31 at 2:12 PM
I'm reading $TSVT 14D9 with the background of the merger and I have a feeling that Party A was $LYEL (proposal to do all-stock merger) and party B was $BLUE ( proposal to buy certain assets of BLUE for 75M at the bankruptcy auction) https://www.sec.gov/Archives/edgar/data/1860782/000114036125013644/ny20046860x1_sc14d9.htm#tIT4
2 · Reply
Stockstockerr
Stockstockerr May. 29 at 3:40 PM
$TSVT hi
0 · Reply
StockBraker
StockBraker May. 13 at 11:16 AM
$TSVT https://www.nasdaqtrader.com/Trader.aspx?id=TradeHalts
0 · Reply
WAYWARD_SUN
WAYWARD_SUN May. 12 at 11:55 PM
$TSVT
0 · Reply
TwongStocks
TwongStocks May. 12 at 5:09 PM
$TSVT Tender offer expected to close tonight https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-240 "The subsequent merger is tentatively scheduled to close prior to the market open on May 13, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 12, 2025 . If the merger closes as planned, the stock will remain halted on the day of closing (May 13th) and will be suspended effective May 14, 2025. "
0 · Reply
Armonica423
Armonica423 May. 10 at 5:37 PM
$TSVT Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply
BioTechChap
BioTechChap May. 10 at 3:43 PM
$IOVA one more to add: $TSVT. Missed out on M&A, won’t let that happen again.
1 · Reply
Andycap
Andycap May. 2 at 8:59 PM
$TSVT the sentiment makes no sense. They are going through a merger and the new company is buying all outstanding shares at a set price of $5. This stock won't breakout any higher than $5. Goldman will make sure it doesn't.
0 · Reply
Latest News on TSVT
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

May 7, 2025, 4:05 PM EDT - 6 weeks ago

2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

Apr 16, 2025, 5:16 PM EDT - 2 months ago

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

BMY

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 25, 2025, 4:05 PM EDT - 3 months ago

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

Mar 11, 2025, 3:31 PM EDT - 3 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

BMY

Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal

Mar 11, 2025, 10:17 AM EDT - 3 months ago

Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal

BMY

Top 3 Health Care Stocks That May Keep You Up At Night In Q1

Mar 11, 2025, 8:55 AM EDT - 3 months ago

Top 3 Health Care Stocks That May Keep You Up At Night In Q1

SNY VRTX

Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million

Mar 11, 2025, 7:17 AM EDT - 3 months ago

Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million

BMY

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

Mar 10, 2025, 10:17 PM EDT - 3 months ago

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

BMY

2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference

Feb 25, 2025, 7:00 AM EST - 4 months ago

2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results

Feb 6, 2025, 7:03 AM EST - 4 months ago

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Jan 13, 2025, 6:10 PM EST - 5 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

2seventy bio, Inc. (TSVT) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 11:16 AM EST - 7 months ago

2seventy bio, Inc. (TSVT) Q3 2024 Earnings Call Transcript

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

Nov 12, 2024, 7:00 AM EST - 7 months ago

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

Nov 4, 2024, 4:01 PM EST - 8 months ago

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against 2seventy bio, Inc. (TSVT) And Encourages Shareholders to Reach Out

Oct 11, 2024, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against 2seventy bio, Inc. (TSVT) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against 2seventy bio, Inc. (TSVT) and Encourages Shareholders to Learn More About the Investigation

Oct 10, 2024, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against 2seventy bio, Inc. (TSVT) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating 2seventy bio, Inc. (TSVT) And Encourages Investors to Connect

Oct 9, 2024, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating 2seventy bio, Inc. (TSVT) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages 2seventy bio, Inc. (TSVT) Stockholders to Inquire about Securities Investigation

Oct 8, 2024, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages 2seventy bio, Inc. (TSVT) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Reach Out

Oct 7, 2024, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Connect

Oct 6, 2024, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Connect

Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability

Sep 25, 2024, 11:56 AM EDT - 9 months ago

Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability

BMY

2seventy Bio stops enrolling patients in blood cancer therapy study

Sep 25, 2024, 6:51 AM EDT - 9 months ago

2seventy Bio stops enrolling patients in blood cancer therapy study

2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance

Sep 25, 2024, 6:00 AM EDT - 9 months ago

2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance

2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference

Aug 29, 2024, 7:00 AM EDT - 10 months ago

2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference

2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 4:52 AM EDT - 11 months ago

2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript

2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress

Aug 7, 2024, 7:00 AM EDT - 11 months ago

2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress

2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024

Aug 5, 2024, 7:00 AM EDT - 11 months ago

2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024

2seventy bio's Abecma: Compelling Investment In Multiple Myeloma Despite Competition

Jul 9, 2024, 7:06 AM EDT - 1 year ago

2seventy bio's Abecma: Compelling Investment In Multiple Myeloma Despite Competition

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

Jun 26, 2024, 4:11 PM EDT - 1 year ago

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

2seventy bio to Participate in Upcoming Investor Conferences

May 23, 2024, 7:00 AM EDT - 1 year ago

2seventy bio to Participate in Upcoming Investor Conferences

2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript

May 8, 2024, 3:15 PM EDT - 1 year ago

2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

May 8, 2024, 7:00 AM EDT - 1 year ago

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

May 3, 2024, 7:00 AM EDT - 1 year ago

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

Apr 3, 2024, 9:34 AM EDT - 1 year ago

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

Apr 1, 2024, 7:30 AM EDT - 1 year ago

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

Mar 20, 2024, 5:04 PM EDT - 1 year ago

2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

fantastex
fantastex Jun. 4 at 8:04 PM
$LYEL this Will get either bought out or merged with $TSVT for a premium. If released data is positive, get ready, it can pump up more to 20 bucks and bought out for 30.
0 · Reply
fantastex
fantastex Jun. 1 at 6:09 PM
$LYEL manufacturing site is in Bothel, WA - same city where the recent $TSVT acquirer ( $BMY) has its own.... Lol it would be easy for the CEOs to have meetings... Coincidence? @valueforme
2 · Reply
valueforme
valueforme May. 31 at 2:12 PM
I'm reading $TSVT 14D9 with the background of the merger and I have a feeling that Party A was $LYEL (proposal to do all-stock merger) and party B was $BLUE ( proposal to buy certain assets of BLUE for 75M at the bankruptcy auction) https://www.sec.gov/Archives/edgar/data/1860782/000114036125013644/ny20046860x1_sc14d9.htm#tIT4
2 · Reply
Stockstockerr
Stockstockerr May. 29 at 3:40 PM
$TSVT hi
0 · Reply
StockBraker
StockBraker May. 13 at 11:16 AM
$TSVT https://www.nasdaqtrader.com/Trader.aspx?id=TradeHalts
0 · Reply
WAYWARD_SUN
WAYWARD_SUN May. 12 at 11:55 PM
$TSVT
0 · Reply
TwongStocks
TwongStocks May. 12 at 5:09 PM
$TSVT Tender offer expected to close tonight https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-240 "The subsequent merger is tentatively scheduled to close prior to the market open on May 13, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 12, 2025 . If the merger closes as planned, the stock will remain halted on the day of closing (May 13th) and will be suspended effective May 14, 2025. "
0 · Reply
Armonica423
Armonica423 May. 10 at 5:37 PM
$TSVT Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply
BioTechChap
BioTechChap May. 10 at 3:43 PM
$IOVA one more to add: $TSVT. Missed out on M&A, won’t let that happen again.
1 · Reply
Andycap
Andycap May. 2 at 8:59 PM
$TSVT the sentiment makes no sense. They are going through a merger and the new company is buying all outstanding shares at a set price of $5. This stock won't breakout any higher than $5. Goldman will make sure it doesn't.
0 · Reply
Sanesh
Sanesh Apr. 27 at 6:32 PM
$TSVT
0 · Reply
PenkeTrading
PenkeTrading Apr. 24 at 9:37 AM
I found you a Golden Cross on the daily chart of 2Seventy Bio Inc. $TSVT #GoldenCross #NASDAQ
0 · Reply
GOLDENSAFEBETS
GOLDENSAFEBETS Apr. 23 at 2:58 PM
$TSVT any freaking day now
0 · Reply
stocklion2
stocklion2 Apr. 16 at 6:15 AM
$TSVT The company trading under the symbol $ NOVA has a net asset value of $2.7 billion, yet it’s currently sitting at a market cap of just $30 million. These shares are massively undervalued — grab them while they’re still cheap!
0 · Reply
scott52
scott52 Mar. 31 at 1:44 PM
$TSVT who would have thought that BLUE and TSVT would be the only two stable biotechs in a downward market LOL.
0 · Reply
StockBraker
StockBraker Mar. 30 at 12:20 PM
$BLUE $TSVT - Possible Investment Strategy For those that are still holding your TSVT shares from the spinoff - A strategy may be to sell them off now from about $4.95 rather than wait until 2H25 and use those proceeds to buy BLUE. There is no CVR offer for TSVT and once the BLUE deal closes you get those proceeds back (likely sooner) plus the CVR shares. IMHO there's little upside left for TSVT and a longer wait and you gain the addition of future CVR payout (no guarantee) or potentially a sweeter deal on BLUE if there is a bidding war or revised deal.
2 · Reply
Peterson28
Peterson28 Mar. 26 at 1:27 AM
$TSVT Terrible Q1 result. Lucky they got this sold otherwise, the stock is going drop 80% because of the catastrophic Q1 result. Likely Blue will see a similar crazy week Q1 result $BLUE
2 · Reply
d_risk
d_risk Mar. 26 at 1:20 AM
$TSVT - 2seventy bio Inc. Common Stock - 10K - Updated Risk Factors TSVT's 2025 10-K Risk Factors highlight new challenges from the proposed BMS acquisition, funding needs for Abecma, regulatory hurdles, privacy law complexities, and potential market-wide liquidity issues, alongside ongoing concerns about profitability, IP protection, and compliance risks. 🟢 Added 🟠 Removed https://d-risk.ai/TSVT/10-K/2025-03-25
0 · Reply
DonCorleone77
DonCorleone77 Mar. 25 at 8:13 PM
$TSVT 2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year Reports Q4 revenue $2.9M, consensus $13.03M. "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure and focus solely on Abecma," said Chip Baird, chief executive officer, 2seventy bio. "This week marks four years since Abecma received FDA approval as the first anti-BCMA CAR T cell therapy approved for relapsed or refractory multiple myeloma. Together with BMS, we remain committed to expanding the reach of this important therapy. We launched 2seventy with the goal of providing more time to patients, and we believe with BMS' experience and resources, we can continue to improve outcomes for people living with multiple myeloma."
0 · Reply
27R
27R Mar. 24 at 6:23 PM
$TSVT earnings approaching. Analysts anticipate revenue growth aligning with recent operational scaling. Options flow shows heightened near-term call interest, implying cautious optimism. Focus remains on margin sustainability and pipeline execution. Key metrics could drive volatility.
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 21 at 2:31 PM
$TSVT Abecma looking promising. Multiple myeloma market evolving fast. Watching closely as 2seventy approaches breakeven. Partnership with BMS adds credibility. Might scale into position if Q1 shows strong momentum. thorough article: https://beyondspx.com/article/2seventy-bio-inc-tsvt-navigating-the-evolving-multiple-myeloma-landscape-with-abecma
0 · Reply
Ashabibi
Ashabibi Mar. 21 at 12:05 PM
$IOVA if you look at the charts for the companies that got acquired $CKPT , $TSVT and $OPTN you'll notice the price was brought down to the gutter in the months leading to the buyout. I see a similar pattern here. Big pharma probably gonna offer around $15 per share..but we'll see a buyout non the less.
3 · Reply